Abeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences
April 05 2017 - 7:43AM
Company CEO to Co-Chair Symposium being
held on April 11th in NYC
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage
biopharmaceutical company focused on developing novel gene
therapies for life-threatening rare genetic diseases, is pleased to
announce a Gene Therapy for Rare Diseases Symposium with the New
York Academy of Sciences (NYAS) and the Biochemical Pharmacology
Discussion Group in New York City on April 11th, 2017.
“We are pleased to co-host this unique gene
therapy symposium that highlights the importance of outcome
measurements in gene therapy trial design, preclinical strategies,
new clinical redosing paradigms and combination approaches for
treating rare diseases,” stated Timothy J. Miller, PhD, President
& CEO of Abeona Therapeutics.
Website & Webinar Link:
http://www.nyas.org/RareDiseases
About New York Academy of
Sciences: The New York Academy of Sciences (NYAS) is an
independent, not-for-profit organization that since 1817 has been
committed to advancing science, technology, and society worldwide.
With 25,000 members around the world, the Academy is creating a
global community of science for the benefit of humanity. The
Academy's core mission is to advance scientific knowledge,
positively impact the major global challenges of society with
science-based solutions, and increase the number of scientifically
informed individuals in society at large. Please visit us online
at www.nyas.org.
About the Biochemical Pharmacology
Discussion Group: The Biochemical Pharmacology Discussion
Group represents a diverse group of scientists from pharmaceutical
and biotechnology companies and university and medical research
centers interested in biochemistry, molecular biology, biomedical
research, and related areas. The group brings together diverse
institutions and communities, industrial and academic, to share new
and relevant information at the frontiers of research and
development. The group also serves as the Biochemical Topical
Group for the American Chemical Society's New York Chapter.
About Abeona: Abeona
Therapeutics Inc. is a leading clinical-stage biopharmaceutical
company developing gene therapies for life-threatening rare genetic
diseases. Abeona's lead programs include ABO-102 (AAV-SGSH) and
ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene
therapies for Sanfilippo syndrome (MPS IIIA and IIIB,
respectively). Abeona is also developing EB-101 (gene-corrected
skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB),
EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene
therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene
therapy for treatment of infantile Batten disease (INCL), and
ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302
using a novel CRISPR/Cas9-based gene editing approach to gene
therapy for rare blood diseases. In addition, Abeona has a
plasma-based protein therapy pipeline, including SDF Alpha™
(alpha-1 protease inhibitor) for inherited COPD, using its
proprietary SDF™ (Salt Diafiltration) ethanol-free process. For
more information, visit www.abeonatherapeutics.com.
This press release contains certain statements
that are forward-looking within the meaning of Section 27a of the
Securities Act of 1933, as amended, and that involve risks and
uncertainties. These statements are subject to numerous risks and
uncertainties, including but not limited to continued interest in
our rare disease portfolio, our ability to enroll patients in
clinical trials, the impact of competition; the ability to develop
our products and technologies; the ability to achieve or obtain
necessary regulatory approvals; the impact of changes in the
financial markets and global economic conditions; and other risks
as may be detailed from time to time in the Company's Annual
Reports on Form 10-K and other reports filed by the Company with
the Securities and Exchange Commission. The Company undertakes no
obligations to make any revisions to the forward-looking statements
contained in this release or to update them to reflect events or
circumstances occurring after the date of this release, whether as
a result of new information, future developments or otherwise.
Investor Contact:Christine Silverstein Vice
President, Investor Relations Abeona Therapeutics Inc. +1
(212)-786-6212 csilverstein@abeonatherapeutics.com
Media Contact:Andre’a Lucca Vice President,
Communications & Operations Abeona Therapeutics Inc. +1
(212)-786-6208alucca@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024